|
시장보고서
상품코드
1394215
글루타티온 수지 시장 평가 : 포장 유형별, 용도별, 지역별, 기회 및 예측(2016-2030년)Glutathione Resin Market Assessment, By Packaging Type [Less Than 50 ml, 50-100 ml, Greater Than 100 ml], By Application [Protein Purification, Laboratories Research, Others], By Region, Opportunities and Forecast, 2016-2030F |
||||||
세계 글루타티온 수지 시장 규모는 2022년 4억 5,130만만 달러에서 2030년 7억 9,290만 달러에 달할 것으로 예상되며, 2023-2030년의 예측 기간 동안 CAGR 7.3%로 성장할 것으로 예상됩니다.
글루타티온 화합물을 아가로스 비드에 적절한 수의 원자 스페이서로 결합하여 정제 중 장애 효과를 감소시키는 비용 효율적인 단백질 정제 공정을 위한 솔루션이 자주 검토되고 있습니다. Thermo Fisher Scientific Inc.는 12개의 원자 스페이서를 통해 글루타티온 화합물을 아가로스 비드에 연결하여 입체 장애를 실질적으로 최소화하는 Pierce Glutathione을 개발했습니다. Pierce 글루타티온을 개발하는데 성공했습니다.
이 회사는 FPLC 전달 용도를 위해 사전 포장된 크로마토그래피 카트리지로 Pierce 글루타티온 아가로스 제품을 제공합니다. 이 제품은 세포 용해액에서 GST 태그가 부착된 융합 단백질을 친화적으로 정제할 수 있는 높은 성능과 용량을 제공하며, Pierce 글루타티온 수지는 경제적인 가격으로 정제 성능과 결합 능력의 손실 없이 5회까지 사용할 수 있어 비용 효율적인 제품입니다. 이 제품은 포유류 및 박테리아 세포 배양물에서 추출 및 정제할 수 있는 세포 용해 시약과 함께 사용할 수 있는 것으로 임상적으로 검증되었습니다.
코로나19의 발생은 모든 사람을 감염에 취약하게 만들었고, 많은 부문과 사람들의 삶에 심각한 영향을 미쳤습니다. 제약 연구 투자 감소에 따른 연구소의 폐쇄는 경제의 안정성을 악화시켰습니다. 그러나 코로나19에 대응하는 효과적인 약물 개발의 시급성은 장애 효과를 줄이면서 글루타티온-S-트랜스퍼라제(GST) 태그가 붙은 재조합 단백질의 신속한 정제를 통합하는 글루타티온 수지에 대한 여러 기회를 창출했습니다. 팬데믹 상황으로 인해 시장이 확대되고 기업이 서비스를 도입할 수 있는 큰 잠재력을 창출하고 있습니다.
글루타티온 수지 시장은 고급 최적화 단백질 정제 공정에 대한 수요가 증가함에 따라 꾸준히 성장하고 있으며, Cytiva는 글루타티온-S-트랜스퍼라제(GST) 태그가 부착된 단백질의 일괄 정제를 위한 친밀감 크로마토그래피 수지인 Glutathione Sepharose 4B 제품을 개발하여 높은 결합력을 달성했습니다. 이 글루타티온 수지는 일반적으로 사용되는 모든 수성 완충액에 대해 화학적으로 안정적이며, 단백질 간 상호작용 연구에 널리 사용되고 있습니다.
이 보고서는 세계의 글루타티온 수지 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황과 전망 등의 정보를 제공합니다.
Global glutathione resin market size was valued at USD 451.3 million in 2022, which is expected to reach USD 792.9 million in 2030, with a CAGR of 7.3% for the forecast period between 2023 and 2030.
Protein purification processes are successively achieved using affinity chromatography, which offers high selectivity, resolution, and capacity in much less time. An effective design affinity chromatography, glutathione resin is a one-step purification process used for recombinant glutathione S-transferase (GST) fusion proteins and relevant binding proteins in insect cells, E. coli, and mammalian cells. Glutathione resin is widely considered an excellent compound for high-performance purifications, especially when high binding capacity is required for batch purification. Elevated glutathione (GSH) levels are significantly observed in several types of cancer cells that increase antioxidant capacity.
Glutathione affinity resins are designed to purify glutathione-S-transferase (GST)-tagged recombinant proteins rapidly. High binding capacity and yield of glutathione-S-transferase (GST) fusion proteins of 5-8 mg/ml settled resin is successfully developed by Merck KGaA, Darmstadt. Also, biological companies are successfully researching to develop cost-effective purification processes while reducing hinderance effect.
Glutathione is an essential compound that increases the immune system and provides a barrier to harmful diseases prone to humans. The rapid purification of glutathione-binding proteins from yeast, insect, bacteria, and glutathione-S-transferase (GST)-tagged recombinant proteins are accomplished by simply designing glutathione affinity resin.
The glutathione ligand is coupled to highly cross-linked 4% agarose beads to optimize and provide high binding capacity for GST-tagged proteins. Flow dependent characteristics is associated with binding of GST to glutathione and lower flow rates usually enhancing the binding capacity.
Merck KGaA, Darmstadt has introduced the trademark product GST. Bind Resins utilize a 14-atom spacer arm to covalently attach reduced glutathione by using sulfide linkage. The yield of glutathione-S-transferase (GST) fusion proteins of 5-8 mg/ml settled resin are achieved by a high degree substation of glutathione, ensuring high binding capacity. In November 2022, LTS Lohmann, a prominent producer of needle-free drug delivery systems, especially transdermal patches, had an investment of USD 14 million with the Global Health Investment Corporation. In addition to successive investment in June 2022, Evonik has partnered with the United States Government, by investing USD 220 million to build innovative drug delivery system for new lipid production facility for mRNA-based therapies.
The solution for a cost-effective purification process for proteins is frequently explored where the glutathione compound is linked to agarose beads with a suitable number of atom spacers that reduces the hindrance effect while undergoing purification. The innovation to develop such cost-effective compounds is accelerating and companies are conducting research in the field. Thermo Fisher Scientific Inc. has successfully developed pierce glutathione where the glutathione compound is linked to agarose beads through 12-atom spacer that substantially minimizes steric hinderance.
The company provides pierce glutathione agarose products in prepacked chromatography cartridges for delivering FPLC applications. The product delivers high performance and capacity properties for affinity purification of GST-tagged fusion proteins from cellular lysates. The pierce glutathione resin is economically priced and can be used five times without compromising purification performance and binding capacity which makes the product cost-effective. The product is clinically validated for its effective use with company's cell lysis reagents to extract and purify from mammalian or bacterial cell cultures.
Immune activity can be enhanced using nutritional or therapeutic composition while performing treatment of mammals. Glutathione precursor comprises of mixtures of glutamic acid, cystine, and glycine along with essential active ingredients like selenium. Selenium is a prominent trace metal found in various food compositions and is significantly incorporated in several non-toxic, water soluble organic or inorganic. Enhancement in cellular and tissue concentrations of glutathione improves resistance to infective agents by improving the immune system. Nutritional requirements are not fulfilled due to limited functionality of bacterial pathogens and commensals to metabolites. Hence, glutathione (GSH) is recognized as an abundant sulfur-content antioxidant present in mammalian tissues and is an incredible source of nutrient sulfur for human pathogens like staphylococcus aureus.
The data published by the Good Food Institute states that, in 2020 the United States market for plant-based foods is around USD 7.4 billion. Plant-based eggs are a modest category that is growing exponentially reaching around USD 39 million in 2021. The growing plant-based products are attracting various biological industries to improve nutritional characteristics which is subsequently creating market opportunities for glutathione resin market.
The outbreak of COVID-19 has severely impacted numerous sectors and human livelihood where every person was vulnerable to infectious disease. The shutdown of research laboratories accompanied by lower investment in pharmaceutical research has deteriorated the economic stability. But the urgency to develop effective drug to combat COVID-19 has created multiple opportunities for glutathione resin to incorporate rapid purification of glutathione-S-transferase (GST)-tagged recombinant proteins while reducing hinderance effect. The pandemic situation has created enormous potential for the market to expand and derive companies to incorporate services.
The glutathione resin market is successfully growing with the increasing demand for advanced and optimized protein purification process. Cytiva has developed Glutathione Sepharose 4B product which is an affinity chromatography resin for performing batch purification of glutathione-S-transferase (GST)-tagged proteins for attaining high binding capacity. The glutathione resin is chemically stable with all commonly used aqueous buffers and substantially used to study protein-protein interactions. Cytiva is successfully offering other life sciences solutions for undergoing purification GST fusion properties.
In October 2023, Cytiva and RoosterBio successively collaborated improving the exosome purification process for promising gene therapies and other significant modalities and manufacturing exosomes in mass quantities. The effective collaboration is developing prominent platform to provide cost-effective manufacturing solutions.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.